The combined organization will unite world-class technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings. 'Together, we will continue to advance life-changing diagnostic solutions to improve patient outcomes and deliver economic benefits to the healthcare system.' By bringing together Quidel's point-of-care diagnostics with Ortho's vast global reach, there is a substantial opportunity to capitalize on the cross-selling opportunities, move into attractive adjacent markets, and accelerate innovative product expansion and the development of molecular technologies,' said Chris Smith, Chairman and Chief Executive Officer of Ortho.

'Quidel shares our commitment to customers and passion for the patients we serve. We look forward to joining together to continue the strong patient focus that is core to our mission, creating an organization with a shared goal of discovering, developing, and delivering innovative solutions to our customers.' We are impressed by what Ortho has accomplished for patients.

Importantly, our complementary cultures are underpinned by a commitment to our customers, patients, and the communities we serve, reinforcing our confidence in the long-term value creation of this transaction. Stronger leadership position, we expect the combined company will emerge as a global player with top-tier R&D capabilities, a more diverse product pipeline, and broader geographic footprint. 'The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services that enhance the health and well-being of patients across the globe,' said Douglas Bryant, President and Chief Executive Officer of Quidel, who will serve as Chairman and Chief Executive Officer of the combined company. The transaction is expected to close during the first half of fiscal year 2022, subject to customary closing conditions. SAN DIEGO, CA and RARITAN, NJ-(BUSINESS WIRE)- DecemQuidel Corporation (NASDAQ: QDEL) ('Quidel') and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) ('Ortho') today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world's largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho's closing price on Decemand an equity value of approximately $6.0 billion. Increases financial flexibility with combined estimated cost synergies of $90 million by end of year three, and revenue synergies in excess of $100 million by 2025, as well as opportunities for adjusted EBITDA margin expansion, supporting enhanced cash generation. Provides Quidel's expansive point-of-care diagnostics portfolio with access to Ortho's broad global reach across 130-plus countries, accelerating growth for Quidel's existing product portfolio and providing exposure to new, emerging markets.ĭeepens innovation pipeline, diversifies product portfolio, and accelerates product growth, driving sustainable revenue in a combined total addressable market of $50 billion. Strategic, transformational acquisition advances Quidel's global leadership in diagnosticsīrings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Please accept our invitation to attend these P.A.C.E.® accredited activities and help spread awareness and knowledge to the healthcare community regarding tick-borne diseases.Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics This webinar focuses on the transmission, manifestation, diagnosis and treatment of Bartonellosis. The Diversity of Bartonellosis Manifestations and Challenges to Treatment is presented by Monica Embers, Ph.D.This webinar focuses on the high incidence of children in the Lyme disease population and the clinical importance of early detection and diagnosis. Pediatric Lyme Disease: “An Epidemic Within a Pandemic!” is presented by Dr.She has since become a widely-respected advocate and national spokeswoman for Lyme disease prevention and treatment. Olivia Goodreau, Lyme Warrior is presented by Olivia Goodreau, who founded the LivLyme Foundation when she was 12 years old.Quidel is pleased to provide the following webinars on the topic of Lyme Disease: SARS-CoV-2: Testing option and patient care Click Here.Click here to browse webinars focused on various disease states and diagnostic solutions.

Ortho quidel